Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different phenotypes of
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to review the
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your thoughts about
cfDNA Sequencing use in Li-Fraumeni syndrome
Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor
Reducing barriers to care for those with Li-Fraumeni syndrome
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and
Whole Body MRI Anxiety
A unique aspect of the LFSA International Symposium is the intersection of LFS families among globally renowned medical and
Another survey opportunity: Risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome
Another invitation to participate in a study about the risk-reducing mastectomy decision making process for adolescents and young adults
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who consider risk-reducing mastectomies –
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS),
Silvia
I discovered the syndrome in 2018 after breast cancer. My breast surgeon, after reviewing my medical history, suggested I see a geneticist, and that's how
Marina
My name is Marina, I am 43 years old and I discovered I have the syndrome in 2019 after my mother's passing at the age
Barbara
I discovered the syndrome in January 2021, after my uncle underwent genetic testing in an attempt to find a better treatment for the cancer he
Isabel
I discovered Li-Fraumeni syndrome in 2017, after breast cancer at the age of 20. The oncologist requested genetic testing, and I was fortunate to
Janaína
I lost my mother to cancer in 2018. She had two types: lung carcinoma and brain astrocytoma. They mentioned it could be genetic at the
Fernanda
I discovered LFS in 2022 after treatment for advanced breast cancer! I needed to take the test because I lost many paternal relatives to
